Benjamin Enerson
Consejero General en THESEUS PHARMACEUTICALS, INC. .
Perfil
Benjamin Enerson is currently working as Vice President-Legal Affairs at Theseus Pharmaceuticals, Inc. Prior to this, he worked as General Counsel at Finch Therapeutics Group, Inc. and Tremeau Pharmaceuticals, Inc. He completed his undergraduate degree from Vanderbilt University and his graduate degree from Cornell Law School in 2004.
Cargos activos de Benjamin Enerson
| Empresas | Cargo | Inicio |
|---|---|---|
| THESEUS PHARMACEUTICALS, INC. | Consejero General | - |
Antiguos cargos conocidos de Benjamin Enerson.
| Empresas | Cargo | Fin |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Consejero General | - |
Tremeau Pharmaceuticals, Inc.
 Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Consejero General | - |
Formación de Benjamin Enerson.
| Cornell Law School | Graduate Degree |
| Vanderbilt University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Empresas privadas | 2 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Tremeau Pharmaceuticals, Inc.
Tremeau Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tremeau Pharmaceuticals, Inc. engages in the developing and delivering of non-opioid pain therapies. The firm product includes TRM-201 (rofecoxib). The company was founded by Bradford C. Sippy and Mark H. N. Corrigan in 2016 and is headquartered in Concord, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Benjamin Enerson
